Naranjo, Francisco, JR. .
HRN: 26-81-15 Sex: MalePatient Encounter
Audit Details
Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
03/17/2025
CO-AMOXICLAV 625MG (TAB)
03/17/2025
03/19/2025
PO
625mg
TID
Infected Diabetic Foot
Waiting Final Action
Indication: Empiric Type of Infection: Skin & Soft Tissue Compliance to guidelines: Compliant To Guidelines
Initial appropriateness: Yes
Final appropriateness: Yes
Overall appropriateness: Yes